Investors bet Sun Pharma can restore Ranbaxy to health
On the surface, Sun Pharma's $3.2-billion purchase of Indian generics rival Ranbaxy, which is in deep trouble with US regulators over safety lapses, may not look like a great deal.
Apr 13, 2014